When we compared HFI variant frequencies across the 10 kinase groups1 between metastatic and primary tumors, the CMGC (Cyclin-Dependent and Mitogen-Activated Protein kinases), STE (Ste kinases which then activate the MAPK family) and TKL (Tyrosine-Kinase Like) groups had more functional variants in metastatic cancers compared to primary tumors, however the difference reached statistical significance only for the TKL group (P = 0.04). This evidence concerns the gene SULT1E1 and metastatic malignant neoplasm.